OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Updates on cardiovascular outcome trials in diabetes
Oliver Schnell, Lars Rydén, Eberhard Standl, et al.
Cardiovascular Diabetology (2017) Vol. 16, Iss. 1
Open Access | Times Cited: 52
Oliver Schnell, Lars Rydén, Eberhard Standl, et al.
Cardiovascular Diabetology (2017) Vol. 16, Iss. 1
Open Access | Times Cited: 52
Showing 26-50 of 52 citing articles:
Key results from observational studies and real‐world evidence of sodium‐glucose cotransporter‐2 inhibitor effectiveness and safety in reducing cardio‐renal risk
Thomas Nyström
Diabetes Obesity and Metabolism (2024)
Open Access | Times Cited: 2
Thomas Nyström
Diabetes Obesity and Metabolism (2024)
Open Access | Times Cited: 2
SGLT inhibition: a possible adjunctive treatment for type 1 diabetes
Halis Kaan Aktürk, Amanda Rewers, Satish K. Garg
Current Opinion in Endocrinology Diabetes and Obesity (2018) Vol. 25, Iss. 4, pp. 246-250
Closed Access | Times Cited: 17
Halis Kaan Aktürk, Amanda Rewers, Satish K. Garg
Current Opinion in Endocrinology Diabetes and Obesity (2018) Vol. 25, Iss. 4, pp. 246-250
Closed Access | Times Cited: 17
Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease
Pedro Monteiro, Carlos Aguíar, Pedro Matos, et al.
Revista Portuguesa de Cardiologia (English Edition) (2019) Vol. 38, Iss. 10, pp. 721-735
Open Access | Times Cited: 17
Pedro Monteiro, Carlos Aguíar, Pedro Matos, et al.
Revista Portuguesa de Cardiologia (English Edition) (2019) Vol. 38, Iss. 10, pp. 721-735
Open Access | Times Cited: 17
The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark
Lars Holger Ehlers, Mark Lamotte, Mafalda Ramos, et al.
Diabetes Therapy (2022) Vol. 13, Iss. 3, pp. 489-503
Open Access | Times Cited: 9
Lars Holger Ehlers, Mark Lamotte, Mafalda Ramos, et al.
Diabetes Therapy (2022) Vol. 13, Iss. 3, pp. 489-503
Open Access | Times Cited: 9
Update on Management of Type 2 Diabetes for Cardiologists
Mohammed Qureshi, Emily Gammoh, Jawairia Shakil, et al.
Methodist DeBakey Cardiovascular Journal (2018) Vol. 14, Iss. 4, pp. 273-273
Open Access | Times Cited: 15
Mohammed Qureshi, Emily Gammoh, Jawairia Shakil, et al.
Methodist DeBakey Cardiovascular Journal (2018) Vol. 14, Iss. 4, pp. 273-273
Open Access | Times Cited: 15
Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)
Richard F. Pollock, William J. Valentine, Steven P. Marso, et al.
Applied Health Economics and Health Policy (2019) Vol. 17, Iss. 5, pp. 615-627
Open Access | Times Cited: 14
Richard F. Pollock, William J. Valentine, Steven P. Marso, et al.
Applied Health Economics and Health Policy (2019) Vol. 17, Iss. 5, pp. 615-627
Open Access | Times Cited: 14
Drug discovery approaches targeting the incretin pathway
Xinxian Deng, Mojdeh S. Tavallaie, Ran Sun, et al.
Bioorganic Chemistry (2020) Vol. 99, pp. 103810-103810
Closed Access | Times Cited: 13
Xinxian Deng, Mojdeh S. Tavallaie, Ran Sun, et al.
Bioorganic Chemistry (2020) Vol. 99, pp. 103810-103810
Closed Access | Times Cited: 13
The cost–effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark
Lars Holger Ehlers, Mark Lamotte, Mafalda Ramos, et al.
Journal of Comparative Effectiveness Research (2021) Vol. 11, Iss. 1, pp. 29-37
Open Access | Times Cited: 11
Lars Holger Ehlers, Mark Lamotte, Mafalda Ramos, et al.
Journal of Comparative Effectiveness Research (2021) Vol. 11, Iss. 1, pp. 29-37
Open Access | Times Cited: 11
Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice?
Robert H. Eckel, Azeez Farooki, Robert R. Henry, et al.
Clinical Diabetes (2019) Vol. 37, Iss. 4, pp. 316-337
Open Access | Times Cited: 11
Robert H. Eckel, Azeez Farooki, Robert R. Henry, et al.
Clinical Diabetes (2019) Vol. 37, Iss. 4, pp. 316-337
Open Access | Times Cited: 11
Sodium-glucose transporter 2 inhibition and cardiovascular events in patients with diabetes: information from clinical trials and observational real-world data
Giulia Ferrannini, Lars Rydén
Clinical Science (2018) Vol. 132, Iss. 18, pp. 2003-2012
Closed Access | Times Cited: 10
Giulia Ferrannini, Lars Rydén
Clinical Science (2018) Vol. 132, Iss. 18, pp. 2003-2012
Closed Access | Times Cited: 10
Impact of FDA-Required Cardiovascular Outcome Trials on Type 2 Diabetes Clinical Study Initiation From 2008 to 2017
Cameron M. Kieffer, A. Robertson
Therapeutic Innovation & Regulatory Science (2019), pp. 216847901986012-216847901986012
Open Access | Times Cited: 6
Cameron M. Kieffer, A. Robertson
Therapeutic Innovation & Regulatory Science (2019), pp. 216847901986012-216847901986012
Open Access | Times Cited: 6
Efeito da empagliflozina para além do controlo glicémico: benefício cardiovascular em doentes com DMT2 e doença cardiovascular estabelecida
Pedro Monteiro, Carlos Aguíar, Pedro Matos, et al.
Revista Portuguesa de Cardiologia (2019) Vol. 38, Iss. 10, pp. 721-735
Open Access | Times Cited: 6
Pedro Monteiro, Carlos Aguíar, Pedro Matos, et al.
Revista Portuguesa de Cardiologia (2019) Vol. 38, Iss. 10, pp. 721-735
Open Access | Times Cited: 6
Evolution of Glucose-Lowering Drugs for Type 2 Diabetes
Andrew J. Krentz
Elsevier eBooks (2018), pp. 431-454
Closed Access | Times Cited: 5
Andrew J. Krentz
Elsevier eBooks (2018), pp. 431-454
Closed Access | Times Cited: 5
The Effects of Glucose Lowering Agents on the Secondary Prevention of Coronary Artery Disease in Patients with Type 2 Diabetes
Inha Jung, Hyemi Kwon, Se Eun Park, et al.
Endocrinology and Metabolism (2021) Vol. 36, Iss. 5, pp. 977-987
Open Access | Times Cited: 5
Inha Jung, Hyemi Kwon, Se Eun Park, et al.
Endocrinology and Metabolism (2021) Vol. 36, Iss. 5, pp. 977-987
Open Access | Times Cited: 5
Correction to: Updates on cardiovascular outcome trials in diabetes
Oliver Schnell, Lars Rydén, Eberhard Standl, et al.
Cardiovascular Diabetology (2017) Vol. 16, Iss. 1
Open Access | Times Cited: 4
Oliver Schnell, Lars Rydén, Eberhard Standl, et al.
Cardiovascular Diabetology (2017) Vol. 16, Iss. 1
Open Access | Times Cited: 4
Impact of FDA-Required Cardiovascular Outcome Trials on Type 2 Diabetes Clinical Study Initiation From 2008 to 2017
Cameron M. Kieffer, A. Robertson
Therapeutic Innovation & Regulatory Science (2020) Vol. 54, Iss. 3, pp. 640-644
Open Access | Times Cited: 4
Cameron M. Kieffer, A. Robertson
Therapeutic Innovation & Regulatory Science (2020) Vol. 54, Iss. 3, pp. 640-644
Open Access | Times Cited: 4
Macrovascular disease: pathogenesis and risk assessment
Sandro Vella, John R. Petrie
Medicine (2018) Vol. 47, Iss. 2, pp. 65-71
Closed Access | Times Cited: 3
Sandro Vella, John R. Petrie
Medicine (2018) Vol. 47, Iss. 2, pp. 65-71
Closed Access | Times Cited: 3
Microvascular and macrovascular effects of liraglutide
Domenico Cianflone, Ali A. Rizvi, Manfredi Rizzo
International Journal of Cardiology (2019) Vol. 286, pp. 17-18
Closed Access | Times Cited: 3
Domenico Cianflone, Ali A. Rizvi, Manfredi Rizzo
International Journal of Cardiology (2019) Vol. 286, pp. 17-18
Closed Access | Times Cited: 3
Marginal hazard ratio estimates in joint frailty models for heart failure trials
Gerrit Toenges, Antje Jahn‐Eimermacher
Biometrical Journal (2019) Vol. 61, Iss. 6, pp. 1385-1401
Open Access | Times Cited: 3
Gerrit Toenges, Antje Jahn‐Eimermacher
Biometrical Journal (2019) Vol. 61, Iss. 6, pp. 1385-1401
Open Access | Times Cited: 3
The cardiometabolic predictive value of anthropometric parameters, vascular ultrasound indexes and fat depots among patients with high cardiovascular risk: an 8-year prospective cohort study
Maciej Haberka, Monika Matla, Aleksander Siniarski, et al.
Polskie Archiwum Medycyny Wewnętrznej (2022)
Open Access | Times Cited: 2
Maciej Haberka, Monika Matla, Aleksander Siniarski, et al.
Polskie Archiwum Medycyny Wewnętrznej (2022)
Open Access | Times Cited: 2
Inibidores da SGLT2 e suas influências no sistema cardiovascular: uma revisão sistemática
Guilherme Antoneli Silva, Rodolpho Gareti Carreira, Wendell Felipe Garcia, et al.
Revista Eletrônica Acervo Saúde (2020), Iss. 44, pp. e3325-e3325
Open Access | Times Cited: 2
Guilherme Antoneli Silva, Rodolpho Gareti Carreira, Wendell Felipe Garcia, et al.
Revista Eletrônica Acervo Saúde (2020), Iss. 44, pp. e3325-e3325
Open Access | Times Cited: 2
Molecular and clinical roles of incretin-based drugs in patients with heart failure
Bassant Orabi, Rasha Kaddoura, Amr Salah Omar, et al.
Heart Failure Reviews (2018) Vol. 23, Iss. 3, pp. 363-376
Closed Access | Times Cited: 1
Bassant Orabi, Rasha Kaddoura, Amr Salah Omar, et al.
Heart Failure Reviews (2018) Vol. 23, Iss. 3, pp. 363-376
Closed Access | Times Cited: 1
Seguridad de los inhibidores de la dipeptidil peptidasa 4
Francisco Carlos Carramiñana Barrera
Medicina de Familia SEMERGEN (2018) Vol. 44, pp. 10-17
Closed Access | Times Cited: 1
Francisco Carlos Carramiñana Barrera
Medicina de Familia SEMERGEN (2018) Vol. 44, pp. 10-17
Closed Access | Times Cited: 1
Transferability of CVOTs EMPA-REG OUTCOME and LEADER in the real world in Italy
Andrea Da Porto
The Journal of AMD (2019) Vol. 22, Iss. 4, pp. 185-185
Open Access | Times Cited: 1
Andrea Da Porto
The Journal of AMD (2019) Vol. 22, Iss. 4, pp. 185-185
Open Access | Times Cited: 1
Recent Trials on the Cardioprotective Effects of New Generation Anti-diabetic and Lipid-Lowering Agents
Omar Abdelfattah, Ahmed Sayed, Anas Al-Refaei, et al.
Frontiers in clinical drug research. Diabetes and obesity (2023), pp. 117-167
Closed Access
Omar Abdelfattah, Ahmed Sayed, Anas Al-Refaei, et al.
Frontiers in clinical drug research. Diabetes and obesity (2023), pp. 117-167
Closed Access
